J&J(US:JNJ) 智通财经网·2025-12-26 03:39Core Viewpoint - Johnson & Johnson's innovative treatment drug Evotaz (Avenatuzumab injection) has received approval from China's NMPA for treating advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, marking a significant advancement in cancer treatment in China [1][2] Group 1: Product Approval and Benefits - The approval of Avenatuzumab injection provides a more convenient administration method, reducing the administration time from several hours to approximately 5 minutes [1] - Compared to intravenous formulations, the incidence of infusion-related adverse reactions is reduced by 80% [1] - The product utilizes Halozyme's ENHANZE® drug delivery technology, which includes recombinant human hyaluronidase (rHuPH20) [1] Group 2: Market Impact and Patient Needs - Approximately 40% of lung cancer patients in China carry EGFR mutations, indicating a significant unmet medical need within this patient population [2] - The approval of Avenatuzumab injection is seen as a milestone, reinforcing its important role in the treatment of EGFR mutation-positive NSCLC [2] - The new subcutaneous formulation offers greater convenience for patients and clinicians, improving tolerability while maintaining efficacy and manageable safety [2]